Factor IXa as a target for anticoagulation in thrombotic disorders and conditions

Drug Discovery Today

Volumn 19, Issue 9, 2014, Pages 1445-1453

  Smiley, Dia A ^a   Becker, Richard C ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APTAMER; BLOOD CLOTTING FACTOR 9A; MONOCLONAL ANTIBODY; RNA; THROMBOPLASTIN; THROMBIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; CARDIOPULMONARY BYPASS; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEMOSTASIS; HUMAN; MECHANICAL HEART VALVE; REVIEW; THROMBOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; COMPLICATION; DRUG DESIGN; HEMORRHAGE; METABOLISM; PATHOLOGY;

ACUTE CORONARY SYNDROME; ANIMALS; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG DESIGN; FACTOR IXA; HEMORRHAGE; HUMANS; THROMBIN; THROMBOPLASTIN; THROMBOSIS;

EID: 84907857122     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.06.028     Document Type: Article

References (85)

1. V.L. Roger American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics Circulation 125 2012 188 197
2. M. Hoffman Remodeling the blood coagulation cascade J. Thromb. Thrombolysis 16 2003 17 20
3. J.H. Lawson, and K.G. Mann Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation J. Biol. Chem. 266 1991 11317 11327
4. M.D. Boisclair Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1 + 2 Thromb. Haemost. 70 1993 253 258
5. K.A. Bauer Factor IX is activated in vivo by the tissue factor mechanism Blood 76 1990 731 736
6. P.N. Walsh Roles of factor XI, platelets and tissue factor-initiated blood coagulation J. Thromb. Haemost. 10 2003 2081 2086
7. P.H. Bolton-Maggs, and K.J. Pasi Haemophilias A and B Lancet 9371 2003 1801 1809
8. N. Mackman Tissue-specific hemostasis in mice Arterioscler. Thromb. Vasc. Biol. 25 2005 2273 2281
9. J.I. Weitz, and H.R. Buller Direct thrombin inhibitors in acute coronary syndromes: present and future Circulation 105 2002 1004 1011
10. A. Mathur Interaction of factor IXa with factor VIIIa. Effects of protease domain Ca2+ binding site, proteolysis in the autolysis loop, phospholipid, and factor X J. Biol. Chem. 272 1997 23418 23426
11. H.F. Lin A coagulation factor IX-knockout mouse model for human hemophilia B Blood 90 1997 3962 3966
12. H. Chao Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors Mol. Ther. 4 2001 217 222
13. X. Wang Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice J. Thromb. Haemost. 3 2005 695 702
14. S.J. Freedman Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX J. Biol. Chem. 271 1996 16227 16236
15. H. Brandstetter X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B Proc. Natl. Acad. Sci. U. S. A. 92 1995 9796 9800
16. 2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding J. Biol. Chem. 271 1996 25332 25337
17. J.G. Neels Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein Blood 96 2000 3459 3465
18. J.N. Morris Recent history of coronary disease Lancet 1 1951 69 73
19. P. Libby Macrophages and atherosclerotic plaque stability Curr. Opin. Lipidol. 7 1996 330 335
20. E.W. Davie, and J.D. Kulman An overview of the structure and function of thrombin Semin. Thromb. Haemost. 32 2006 3 15
21. J.D. Marmur Identification of active tissue factor in human coronary atheroma Circulation 94 1996 1226 1232
22. E. Tremoli Tissue factor in atherosclerosis Atherosclerosis 144 1999 273 283
23. D.T. Yang Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events Am. J. Clin. Pathol. 126 2006 411 415
24. C.J. Doggen Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII Blood 108 2006 4045 4051
25. M.C. Minnema Activation of clotting factors XI and IX in patients with acute myocardial infarction Arterioscler. Thromb. Vasc. Biol. 20 2000 2489 2493
26. S.S. Ahmad Platelet receptor occupancy with factor IXa promotes factor X activation J. Biol. Chem. 264 1989 20012 20016
27. S.R. Coughlin Thrombin signaling and protease-activated receptors Nature 407 2000 258 264
28. S.V. Rao, and E.M. Ohman Anticoagulant therapy for percutaneous coronary intervention Circ. Cardiovasc. Interv. 3 2010 80 88
29. E. Ovrum Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass Circulation 92 1995 2579 2584
30. L.H. Edmunds Jr. Blood-surface interactions during cardiopulmonary bypass J. Card. Surg. 8 1993 404 410
31. K. Tanaka Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery J. Cardiothorac. Anesth. 3 1989 181 188
32. R.W. Colman Hemostatic complications of cardiopulmonary bypass Am. J. Hematol. 48 1995 267 272
33. B.J. Hunt Activation of coagulation and fibrinolysis during cardiothoracic operations Ann. Thorac. Surg. 65 1998 712 718
34. H. Philippou An ELISA for factor X activation peptide: application to the investigation of thrombogenesis in cardiopulmonary bypass Br. J. Haematol. 90 1995 432 437
35. A. Koster Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation J. Cardiothorac. Vasc. Anesth. 17 2003 171 175
36. S.J. Brister Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant? Thromb. Haemost. 70 1993 259 262
37. S. Khuri Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass Ann. Thorac. Surg. 60 1995 1008 1014
38. T.B. Spanier Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog J. Thorac. Cardiovasc. Surg. 115 1998 1179 1188
39. S.M. Nimjee A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery Mol. Ther. 14 2006 408 415
40. P.P. de Jaegere, and W.J. Suyker Off-pump coronary artery bypass surgery Heart 88 2002 313 318
41. T.B. Spanier Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass J. Thorac. Cardiovasc. Surg. 116 1998 860 869
42. M. Cushman Epidemiology and risk factors for venous thrombosis Semin. Hematol. 44 2007 62 69
43. M. Hoffman Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation Blood 86 1995 1794 1801
44. S. Butenas The significance of circulating factor IXa in blood J. Biol. Chem. 279 2004 22875 22882
45. M.E. Tesselaar Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J. Thromb. Haemost. 5 2007 520 527
46. J. Polgar The P-selectin, tissue factor, coagulation triad J. Thromb. Haemost. 3 2005 1590 1596
47. J.C. Meijers High levels of coagulation factor XI as a risk factor for venous thrombosis N. Engl. J. Med. 342 2000 696 701
48. G.Z. Feuerstein An inhibitory anti-factor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis Thromb. Haemost. 82 1999 1443 1445
49. H.J. Metzner Genetic fusion to albumin improves the pharmacokinetic properties of factor IX Thromb. Haemost. 102 2009 634 644
50. D. Feng Evidence of clinically significant extravascular stores of factor IX J. Thromb. Haemost. 11 2013 2176 2178
51. C.R. Benedict Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model J. Clin. Invest. 88 1991 1760 1765
52. T.A. Drake Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis Am. J. Pathol. 134 1989 1087 1097
53. S.A. Silverberg Kinetics of the activation of bovine coagulation factor X by components of the extrinsic pathway. Kinetic behavior of two-chain factor VII in the presence and absence of tissue factor J. Biol. Chem. 252 1977 8481 8488
54. R.A. Marlar An alternative extrinsic pathway of human blood coagulation Blood 60 1982 1353 1358
55. D.M. Stern In vivo evidence of intravascular binding sites for coagulation factor IX Br. J. Haematol. 66 1987 227 232
56. W.F. Cheung The binding of human factor IX to endothelial cells is mediated by residues 3-11 J. Biol. Chem. 267 1992 20529 20531
57. T.M. Misenheimer The heparin-binding exosite is critical to allosteric activation of factor IXa in the intrinsic tenase complex: the role of arginine 165 and factor X Biochemistry 46 2007 7886 7895
58. H. Atoda Calcium-binding analysis and molecular modeling reveal echis coagulation factor IX/factor X-binding protein has the Ca-binding properties and Ca ion-independent folding of other C-type lectin-like proteins FEBS Lett. 531 2002 229 234
59. W.F. Li A C-type lectin-like protein from Agkistrodon acutus venom binds to both platelet glycoprotein Ib and coagulation factor IX/factor X Biochem. Biophys. Res. Commun. 332 2005 904 912
60. T.F. Choudhri Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage J. Exp. Med. 190 1999 91 99
61. S. Suggett Use of phage display for the generation of human antibodies that neutralize factor IXa function Blood Coagul. Fibrinolysis 11 2000 27 42
62. C.J. Refino A human antibody that inhibits factor IX/IXa function potently inhibits arterial thrombosis without increasing bleeding Arterioscler. Thromb. Vasc. Biol. 22 2002 517 522
63. E.L. Howard Factor IXa inhibitors as novel anticoagulants Arterioscler. Thromb. Vasc. Biol. 27 2007 722 727
64. J.R. Toomey Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosis Thromb. Res. 100 2000 73 79
65. J.R. Toomey Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke Stroke 33 2002 578 585
66. L.J. Benincosa Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys J. Pharmaco. Exp. Ther. 292 2000 810 816
67. B.I. Eriksson Fixit Study Group. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study J. Thromb. Haemost. 6 2008 457 463
68. J.I. Weitz New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 120S 151S
69. C.K. Dyke First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a Phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity Circulation 114 2006 2490 2497
70. M.Y. Chan Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease Circulation 117 2008 2865 2874
71. J.P. Vavalle, and M.G. Cohen The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome Future Cardiol. 8 2012 371 382
72. C.P. Rusconi RNA aptamers as reversible antagonists of coagulation factor IXa Nature 419 2002 90 94
73. T.J. Povsic RADAR Investigators. Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy Eur. Heart J. 32 2011 2412 2419
74. A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI (Regulate). Available at: http://clinicaltrials.gov/show/NCT01848106
75. G.W. Stone HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction N. Engl. J. Med. 358 2008 2218 2230
76. G.W. Stone ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes N. Engl. J. Med. 355 2006 2203 2216
77. Lovenox [package insert]. Laval, Quebec.sanofi-aventis Canada Inc. July 2013
78. Fragmin [package insert]. New York, NY. Pfizer Inc. October 2010
79. Coumadin [package insert]. Princeton, NJ: Bristol-Myers Squibb. October 2011
80. Angiomax [package insert]. Parsipanny, NJ; The Medicines Company. May 2013
81. Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc. January 2013
82. Acova [package insert]. Research Triangle Park, NC: GlaxoSmithKline Inc. April 2012
83. Arixtra [package insert]. Research Triangle Park, NC: GlaxoSmithKline Inc. September 2013
84. Xarelto [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc. November 2012
85. Eliquis [package insert]. Princeton, New Jersey: Bristol-Myers Squibb Inc; December 2012